结直肠癌肝转移精准治疗进展

Advances in the precision treatment of colorectal liver metastases

  • 摘要: 肝转移是结直肠癌治疗失败的主要原因之一,提高肝转移疗效的关键是精准化治疗。寡转移分类标准不仅明确了不同肝转移的治疗手段和治疗目标,且进一步提升了局部非手术治疗的地位。寻找RAS 基因以外具有预后及疗效预测价值的分子标志物,对结直肠癌肝转移(colorectal liver metastases,CRLM)精准治疗意义重大。精准化治疗贯穿CRLM 治疗全程优化管理的各个环节,包括初始可切除肝转移治疗顺序的优化、KRAS基因对肝切除术的疗效预测、转化治疗敏感人群的选择、最佳随访策略的应用及个体化综合治疗方案的制定。本文就CRLM 精准治疗的最新进展进行综述。

     

    Abstract: Liver metastasis is one of the main causes of treatment failure in colorectal cancer, and the key to improve the efficacy of treatment is to adopt precision therapy. Oligometastatic classification clearly defines the treatment methods and goals for distinguish -ing liver metastases, as well as promotes nonsurgical methods for local treatments. In addition to RAS oncogene, other biomarkers with prognostic and therapeutic predictive values urgently need to be identified. Precision therapy encompasses the entire course of optimal treatment in colorectal liver metastases (CRLM) including the following: optimization of therapy sequence for initial resectable liver metastases, treatment predictive value of KRAS oncogene for liver resection, selection of sensitive subgroups for conversion ther -apy, application of the optimal follow-up strategy, and formulation of individual comprehensive treatment regimens. This review focus -es on the recent progress of precision treatment for CRLM.

     

/

返回文章
返回